BRST5:The polygenic component of breast cancer susceptibility: Difference between revisions
| [checked revision] | [pending revision] |
No edit summary |
|||
| (2 intermediate revisions by one other user not shown) | |||
| Line 51: | Line 51: | ||
!Notes | !Notes | ||
|- | |- | ||
| | |Multiple Genes(FGFR2, MAP3K1, TOX3 etc)||Many SNPs (Common, minor allele frequency >1%)||Affect regulatory region or epigenetics rather than traditional oncogenes/tumor suppressor genes ||complex inheritance: non-Mendelian, polygenic pattern; their effects are additive or multiplicative and are often influenced by environment; Penetrance: each SNP confer very modest risk (<1.3 fold), but cumulative penetrance increases with a higher PRS; Expressivity: variable. PRS may influence age of onset, tumor subtype or morphology | ||
| | | | ||
|- | |- | ||
| | | | ||
| | | | ||
| | | | ||
| | | | ||
| Line 76: | Line 75: | ||
!Notes | !Notes | ||
|- | |- | ||
| | | | ||
|Regulatory/epigenetic, not traditional oncogenes/TSGs | |Regulatory/epigenetic, not traditional oncogenes/TSGs | ||
|Common, MAF >1% | |Common, MAF >1% | ||
| Line 114: | Line 113: | ||
!Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | !Gene; Genetic Alteration!!Pathway!!Pathophysiologic Outcome | ||
|- | |- | ||
|'' | |''MAP3K1'' | ||
| | |MAPK/ERK pathway | ||
| | |Alters cell survival and signal transduction | ||
|- | |- | ||
|''FGFR2'' | |''FGFR2'' | ||
|FGF signaling | |FGF signaling | ||
| | |Increases proliferation | ||
|- | |- | ||
|''TOX3'' | |''TOX3'' | ||
| | |Chromatin remodeling | ||
|Affects | |Affects transcriptional regulation and stress response | ||
|- | |- | ||
|''ESR1'' | |''ESR1'' | ||
|Estrogen signaling | |Estrogen receptor signaling | ||
| | |Modulates hormonal response in luminal cells | ||
|- | |- | ||
| | |CDKN2B | ||
| | |Cell cycle checkpoint | ||
| | |Dysregulates cell cycle progression | ||
|} | |} | ||
==Genetic Diagnostic Testing Methods== | ==Genetic Diagnostic Testing Methods== | ||